Project Grant R21AI178183

Award Date 6/10/24
Completion Date 4/30/26
Dollars Obligated $642K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $335,559 to the University of North Carolina at Chapel Hill to conduct a pilot randomized controlled trial on the feasibility, acceptability, and preliminary effectiveness of a Focal Mass Drug Administration (FMDA) program for household members of pregnant women to protect against malaria in pregnancy (MIP). The key...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...
This Project Grant award of $743,488.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under CFDA Program 93.865 Child Health and Human Development Extramural Research, aims to examine the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa. The research objectives are to: 1) characterize the mechanisms mediating the effects of sulfadoxine-pyrimethamine (SP) and dihydroartemisinin-piperaquine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,204 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the London School of Hygiene and Tropical Medicine (LSHTM) to conduct research on complex malaria in India. The key products and services to be delivered through this 5-year project include: Monitoring the changing epidemiology of malaria in Odisha, India through a 4-year community-based cohort study to...
This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...
This Project Grant award of $1,373,790, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to optimize the structural features of the antimalarial compound ELQ-596 for once-monthly oral prophylaxis in humans. The award aims to develop a next generation of ELQ compounds with improved intrinsic anti-plasmodial activity, enhanced oral bioavailability, and extended...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $832,071 to Seattle Children's Hospital to develop a universal transmission-blocking vaccine against malaria. The key products and services to be delivered include: Developing potent transmission-reducing monoclonal antibodies that can block vector infection across Plasmodium falciparum and Plasmodium vivax species. This...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,553,810 to the University of Maryland, Baltimore to conduct genomic surveillance for artemisinin resistance in Africa. The project aims to identify parasite genetic adaptations and functional pathways associated with resistance to artemisinin-based combination therapies, the first-line treatment for malaria in...
This federal Project Grant award of $708,202, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award to Brown University will: 1) conduct a case-control study in Kenya to identify infants and children with severe malaria and matched controls, 2)...
This $505,238 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to identify skin-associated compounds that can disrupt mosquito landing and biting behavior. The overarching goal is to discover new chemical compounds that can act as improved topical insect repellents compared to DEET, especially for use in tropical regions. The research will involve validating...

THE IMPACT OF NOVEL VECTOR CONTROL TOOLS ON ASYMPTOMATIC PLASMODIUM FALCIPARUM INFECTION PREVALENCE AND TRANSMISSION POTENTIAL - THE IMPACT OF NOVEL VECTOR CONTROL TOOLS ON ASYMPTOMATIC PLASMODIUM FALCIPARUM INFECTION PREVALENCE AND TRANSMISSION POTENTIAL PROJECT SUMMARY MALARIA IS A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN MANY COUNTRIES IN THE TROPICS AND SUBTROPICS. MOST MALARIA PROGRAMS FOCUS ON DIAGNOSIS AND TREATMENT OF CLINICAL INFECTIONS AND BLANKET VECTOR CONTROL THROUGH BED NET DISTRIBUTIONS. THIS STRATEGY DOES NOT ADEQUATELY TARGET THE ASYMPTOMATIC RESERVOIR, WHICH IS THE SOURCE OF UP TO 95% OF MALARIA TRANSMISSION. THERE IS A LACK OF UNDERSTANDING OF THE ABILITY OF MANY CURRENT AND NEW MALARIA CONTROL TOOLS TO SHRINK THE ASYMPTOMATIC RESERVOIR BECAUSE MANY STUDIES EVALUATING INTERVENTIONS FOCUS ON CLINICAL INCIDENCE AS THE MAIN OUTCOME. SPATIAL REPELLENTS ARE A NOVEL TOOL FOR MALARIA CONTROL. THEY RELEASE VOLATILE COMPOUNDS THAT DRIVE AWAY MOSQUITOS FROM HOUSES. SPATIAL REPELLENTS MIGHT REDUCE CLINICAL INCIDENCE BY UP TO 50%. THEIR IMPACT ON THE PREVALENCE OF ASYMPTOMATIC INFECTIONS HAS NOT BEEN SYSTEMATICALLY STUDIED. THE ABILITY OF SPATIAL REPELLENTS TO REDUCE CLINICAL INCIDENCE IS CURRENTLY BEING FIELD-TESTED IN A FUNDED LARGE-SCALE CLUSTER RANDOMIZED TRIAL IN WESTERN KENYA. OUR PRELIMINARY DATA SHOWS THAT NEARLY HALF OF ALL INDIVIDUALS IN THE STUDY SITE CARRIED ASYMPTOMATIC MALARIA INFECTIONS AT BASELINE. GIVEN THE IMPORTANCE OF THESE INFECTIONS AS A SOURCE OF TRANSMISSION, THERE IS A NEED TO UNDERSTAND WHETHER SPATIAL REPELLENTS CAN ALSO REDUCE THIS RESERVOIR IN ORDER TO ASSESS THEIR FULL POTENTIAL TO COMBAT MALARIA. HERE, WE PROPOSE TO STUDY THE IMPACT OF SPATIAL REPELLENTS ON ASYMPTOMATIC P. FALCIPARUM PREVALENCE. THE OBJECTIVES OF THIS APPLICATION ARE TO: 1) QUANTIFY REDUCTIONS IN ASYMPTOMATIC PREVALENCE AFTER THE INTRODUCTION OF SPATIAL REPELLENTS. WE WILL SCREEN 9000 BLOOD SAMPLES CURRENTLY BEING COLLECTED FOR P. FALCIPARUM INFECTIONS BY QPCR AND MICROSCOPY. 2) COMPARE MOSQUITO-TO- HUMAN AND HUMAN-TO-MOSQUITO TRANSMISSION IN INTERVENTION AND CONTROL CLUSTERS. WE WILL QUANTIFY GAMETOCYTES AND COMPARE PARASITE AND GAMETOCYTE PREVALENCE AND DENSITY TO VECTOR DENSITY, SPOROZOITE RATE, AND ENTOMOLOGICAL INOCULATION RATE (EIR) AT DIFFERENT TIME POINTS BEFORE AND AFTER BLOOD SAMPLE COLLECTIONS. THE OUTCOMES OF THE PROPOSED RESEARCH INCLUDE: 1) KNOWLEDGE OF THE POTENTIAL OF SPATIAL REPELLENTS TO REDUCE ASYMPTOMATIC PREVALENCE, AND 2) AN UNDERSTANDING OF THE CHANGES IN MOSQUITO-TO-HUMAN AND HUMAN- TO-MOSQUITO TRANSMISSION AFTER INTRODUCTION OF SPATIAL REPELLENTS. OUR DATA ON THE RELATIONSHIPS BETWEEN PARASITOLOGICAL AND ENTOMOLOGICAL MEASURES OF TRANSMISSION INTENSITY, COLLECTED IN 20 CLUSTERS AT THREE TIMEPOINTS, WILL ENABLE A BETTER UNDERSTANDING ON THE IMPACT OF MALARIA CONTROL BEYOND THE USE OF SPATIAL REPELLENTS. OUR WORK AIMS TO ACCELERATE MALARIA ELIMINATION, AND THUS TO IMPROVE THE LIVES OF PEOPLE LIVING IN MALARIA-ENDEMIC COUNTRIES.

Posted 6/10/24, 12:00 AM